Related Experiment Videos
[Endovascular treatment for carotid artery stenosis]
H Gensicke1, S Engelter, L Bonati
1Neurologie, Stroke Unit, Universitätsspital Basel.
Insights
Carotid endarterectomy (CEA) is safer for symptomatic carotid stenosis than carotid artery stenting (CAS), especially for those over 70. Both treatments effectively prevent stroke, but restenosis is more common after CAS.
Area of Science:
- Vascular Surgery
- Neurology
- Interventional Cardiology
Context:
- Internal carotid artery (ICA) stenosis causes 10-15% of ischemic strokes.
- Carotid endarterectomy (CEA) is the standard treatment for symptomatic carotid stenosis, reducing recurrent stroke risk.
- Endovascular techniques like carotid artery stenting (CAS) offer surgical alternatives.
Purpose:
- To compare the risks and benefits of CAS versus CEA for carotid stenosis.
- To summarize evidence from randomized controlled trials on CAS and CEA outcomes.
Summary:
- For symptomatic carotid stenosis, CEA has a lower risk of peri-procedural stroke or death compared to CAS.
- CAS shows reduced risks of myocardial infarction, cranial nerve palsy, and access site hematoma versus CEA.
- CAS is as safe as CEA in patients under 70; however, CAS carries higher stroke risk in older patients (>70).
- Both treatments are equally effective in preventing recurrent stroke in the short term.
- Restenosis is more frequent after CAS, necessitating longer-term follow-up.
Impact:
- CEA is recommended for symptomatic carotid stenosis, particularly in older patients, due to lower peri-procedural risks.
- CAS may be a safer alternative for younger patients or those with specific contraindications to CEA.
- Further research is needed to determine the optimal treatment for asymptomatic carotid stenosis and long-term outcomes of CAS.
- Evidence supports CAS for reducing specific complications like myocardial infarction and nerve palsy.
- Understanding long-term restenosis rates after CAS is crucial for guiding treatment decisions.
Abstract:
About 10 - 15% of all ischaemic strokes are caused by focal atherosclerosis and consecutive narrowing (stenosis) of the internal carotid artery (ICA). Carotid endarterectomy (CEA) - the standard treatment for carotid stenosis - substantially reduces the risk of recurrent stroke among patients who have had ischaemic symptoms such as stroke or transient ischaemic attack attributable to the stenosis. To a smaller extent, CEA also reduces the risk of first stroke in patients with hitherto asymptomatic carotid stenosis. Endovascular treatment techniques, including balloon angioplasty in the initial years and more recently, carotid artery stenting (CAS), have been developed as an alternative to CEA for treating carotid stenosis without necessitating surgery. The present review compares risks and benefits between CAS and CEA summarising the existing evidence derived from randomised controlled trials. Among patients with symptomatic carotid stenosis, CEA is associated with a lower risk of peri-procedural stroke or death than CAS. CAS reduces the risk of peri-procedural myocardial infarction, cranial nerve palsy and access site haematoma compared with CEA. The excess peri-procedural stroke risk associated with CAS appears to be limited to patients older than 70 years while in younger patients, CAS is as safe as CEA. Both treatments are equally effective in preventing recurrent stroke in the first few years following treatment. However, recurrent stenosis appears to be more common after CAS, and longer-term follow-up of ongoing trials should be awaited to investigate whether restenosis might be associated with recurrent stroke. The best treatment approach for patients with asymptomatic carotid stenosis remains to be determined in ongoing clinical trials.
Related Concept Videos
Aneurysm III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management
Aortic Regurgitation III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...